Top Markets
Coin of the day
Damora Therapeutics, Inc. Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

DMRA
Rangering i aksjer #6692
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering... Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Aksjekurs
$30.90
Sist synkronisert: 2026-08-27
Markedsverdi
$1.90B
Endring (1 dag)
1.68%
Endring (1 år)
859.63%
Land
US
Handel Damora Therapeutics, Inc. (DMRA)

Kategori

P/S-forhold for Damora Therapeutics, Inc. (DMRA)
P/S-forhold per 2026 TTM: 0
Ifølge Damora Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Damora Therapeutics, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH